Giulia Degiacomi

University of Pavia

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (11)

Year:

2023

Year:

2023

Year:

2022

Year:

2022

The discontinuation of TB services due to COVID-19 causes concern about a future resurgence of TB, also considering that latent infection affects a high number of people worldwide. To combat this situation, the identification of antitubercular compounds targeting Mycobacterium tuberculosis through novel mechanisms of action is necessary.

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (9)

Maria Rosalia PASCA

Professore Ordinario BIO/19

Università degli Studi di Pavia

ITALY

View details

ELENA PETRICCI

Professor

University of Siena

ITALY

View details

RICCARDO MANGANELLI

Professor

University of Padua

ITALY

View details

Fabrizio Manetti

Professor of Medicinal Chemistry

University of Siena

ITALY

View details

Philippe Loiseau

Professor

Université Paris-Saclay

FRANCE

View details

Giovanni Stelitano

University of Pavia

ITALY

View details

Christian Lherbet

CNRS Délégation Midi-Pyrénées

FRANCE

View details

Laurent Roberto Chiarelli

Associate Professor

Università degli Studi di Pavia

ITALY

View details

Santiago Ramón-García

Universidad de Zaragoza

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Giulia Degiacomi

Research Interests

Explore related searches

Contact this professor

Articles (11)

Mechanochemical Studies on Coupling of Hydrazines and Hydrazine Amides with Phenolic and Furanyl Aldehydes—Hydrazones with Antileishmanial and Antibacterial Activities

Mycobacterium abscessus Infections in Cystic Fibrosis Individuals: A Review on Therapeutic Options

New Drugs and Novel Cellular Targets against Tuberculosis

The Veterinary Anti-Parasitic Selamectin Is a Novel Inhibitor of the Mycobacterium tuberculosis DprE1 Enzyme

A New Benzothiazolthiazolidine Derivative, 11726172, Is Active <i>In Vitro</i> , <i>In Vivo</i> , and against Nonreplicating Cells of Mycobacterium tuberculosis

A Coumarin-Based Analogue of Thiacetazone as Dual Covalent Inhibitor and Potential Fluorescent Label of HadA in Mycobacterium tuberculosis

The Antimalarial Mefloquine Shows Activity against <i>Mycobacterium abscessus</i>, Inhibiting Mycolic Acid Metabolism

Age-related changes in PD-1 expression coincide with increased cytotoxic potential in Vδ2 T cells during infancy

Nitric oxide-releasing compounds for the treatment of lung infections

Design and Synthesis of Pyrano[3,2-b]indolones Showing Antimycobacterial Activity

In vitro Study of Bedaquiline Resistance in Mycobacterium tuberculosis Multi-Drug Resistant Clinical Isolates.

Collaborators (9)

Maria Rosalia PASCA

ELENA PETRICCI

RICCARDO MANGANELLI

Fabrizio Manetti

Philippe Loiseau

Giovanni Stelitano

Christian Lherbet

Laurent Roberto Chiarelli

Santiago Ramón-García

Make your next move.